Assessing the Safety of Human Pluripotent Stem Cells and Their Derivatives for Clinical Applications

Peter W. Andrews, Uri Ben-David, Nissim Benvenisty, Peter Coffey, Kevin Eggan, Barbara B. Knowles, Andras Nagy, Martin Pera, Benjamin Reubinoff, Peter J. Rugg-Gunn, Glyn N. Stacey

Research output: Contribution to journalArticleOtherpeer-review

33 Citations (Scopus)


Pluripotent stem cells may acquire genetic and epigenetic variants during culture following their derivation. At a conference organized by the International Stem Cell Initiative, and held at The Jackson Laboratory, Bar Harbor, Maine, October 2016, participants discussed how the appearance of such variants can be monitored and minimized and, crucially, how their significance for the safety of therapeutic applications of these cells can be assessed. A strong recommendation from the meeting was that an international advisory group should be set up to review the genetic and epigenetic changes observed in human pluripotent stem cell lines and establish a framework for evaluating the risks that they may pose for clinical use.

Original languageEnglish
Number of pages4
JournalStem Cell Reports
Issue number1
Publication statusPublished - 11 Jul 2017

Cite this